



Technology Opportunity, Ref. No. UZ-10/001

Novel Biomarkers for metabolic syndrome

Background

Overweighed and obese patients with insulin resistance (metabolic syndrome) often warrant aggressive management of underlying risk factors to optimize prevention of cardiovascular disease or diabetes. However, only a fraction of patients fulfilling the criteria for a metabolic syndrome are in fact on risk to develop diabetes or cardiovascular diseases. Today, risk stratification strategies are based on general and rather unspecific markers like triglycerides, body weight, blood cholesterol or blood pressure which result in a great overestimation of patients at risk.

New Findings

This invention is based on the analysis of several novel lipid markers in the human blood which are associated with an increased risk to develop a metabolic disease like the metabolic syndrome, diabetes and associated cardiovascular complication. These novel markers are useful in the risk assessment of overweighed and obese patients and for the monitoring of therapeutic interventions. The markers show a diagnostic sensitivity of more than 82% (at a selectivity of 80%) for the metabolic syndrome and can be used in combination with other classical biomarkers to further improve sensitivity and specificity.

Patent Status and Contact

A patent application covering the invention has been filed. We are looking for an industrial partner to exploit the commercial potential of the invention.

Contact: Unitetra, Technology Transfer Office University of Zurich
Mr. Adrian Sigrist, Ref. UZ-08/287
Möhrlistrasse 23, CH-8006 Zürich (Switzerland)
Tel. ++41-44-634 44 01, Fax ++41-44-634 44 09
Email: mail@unitetra.ch, Web: www.unitetra.ch